Which has better earnings and valuation, TWST or IMTX?

Twist Bioscience has higher revenue and earnings than Immatics. Twist Bioscience is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $376.57M 16.51 -$77.67M -$1.33 N/A Immatics $54.60M 23.38 -$222.26M -$1.99 N/A

Is TWST or IMTX more profitable?

Twist Bioscience has a net margin of -19.85% compared to Immatics' net margin of -572.35%. Twist Bioscience's return on equity of -26.73% beat Immatics' return on equity. Company Net Margins Return on Equity Return on Assets Twist Bioscience -19.85% -26.73% -19.15% Immatics -572.35% -47.36% -39.35%

Immatics (IMTX) Competitors

$9.52 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$9.44 -0.08 (-0.84%)

As of 07:35 AM Eastern

Compare

IMTX vs. TWST, XENE, AMRX, CRSP, and TVTX

Should you buy Immatics stock or one of its competitors? MarketBeat compares Immatics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immatics include Twist Bioscience (TWST), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), CRISPR Therapeutics (CRSP), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry.

How does Immatics compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

64.4% of Immatics shares are owned by institutional investors. 3.1% of Twist Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Twist Bioscience currently has a consensus target price of $74.60, suggesting a potential downside of 25.28%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 118.49%. Given Immatics' higher probable upside, analysts clearly believe Immatics is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Twist Bioscience has higher revenue and earnings than Immatics. Twist Bioscience is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	16.51	-$77.67M	-$1.33	N/A
Immatics	$54.60M	23.38	-$222.26M	-$1.99	N/A

Twist Bioscience has a net margin of -19.85% compared to Immatics' net margin of -572.35%. Twist Bioscience's return on equity of -26.73% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-19.85%	-26.73%	-19.15%
Immatics	-572.35%	-47.36%	-39.35%

Twist Bioscience has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Immatics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

In the previous week, Twist Bioscience had 12 more articles in the media than Immatics. MarketBeat recorded 13 mentions for Twist Bioscience and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat Twist Bioscience's score of 0.22 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Twist Bioscience	Neutral
Immatics	Very Positive

Summary

Twist Bioscience beats Immatics on 11 of the 16 factors compared between the two stocks.

How does Immatics compare to Xenon Pharmaceuticals?

Xenon Pharmaceuticals (NASDAQ:XENE) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Xenon Pharmaceuticals presently has a consensus target price of $77.20, indicating a potential upside of 29.23%. Immatics has a consensus target price of $20.80, indicating a potential upside of 118.49%. Given Immatics' higher probable upside, analysts clearly believe Immatics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Xenon Pharmaceuticals has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%
Immatics	-572.35%	-47.36%	-39.35%

95.4% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 4.1% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than Immatics. MarketBeat recorded 2 mentions for Xenon Pharmaceuticals and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat Xenon Pharmaceuticals' score of 0.96 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Xenon Pharmaceuticals	Positive
Immatics	Very Positive

Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Immatics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

Immatics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenon Pharmaceuticals	N/A	N/A	-$345.91M	-$4.70	N/A
Immatics	$54.60M	23.38	-$222.26M	-$1.99	N/A

Summary

Immatics beats Xenon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Immatics compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Immatics	-572.35%	-47.36%	-39.35%

Amneal Pharmaceuticals has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.05B	1.80	$72.06M	$0.38	45.34
Immatics	$54.60M	23.38	-$222.26M	-$1.99	N/A

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat Amneal Pharmaceuticals' score of 0.42 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Neutral
Immatics	Very Positive

Amneal Pharmaceuticals currently has a consensus price target of $15.80, indicating a potential downside of 8.30%. Immatics has a consensus price target of $20.80, indicating a potential upside of 118.49%. Given Immatics' higher probable upside, analysts clearly believe Immatics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Amneal Pharmaceuticals has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Immatics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Immatics on 9 of the 15 factors compared between the two stocks.

How does Immatics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Immatics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

CRISPR Therapeutics currently has a consensus price target of $67.78, indicating a potential upside of 23.41%. Immatics has a consensus price target of $20.80, indicating a potential upside of 118.49%. Given Immatics' stronger consensus rating and higher possible upside, analysts clearly believe Immatics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Immatics has a net margin of -572.35% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Immatics	-572.35%	-47.36%	-39.35%

Immatics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$1M	5,296.98	-$581.60M	-$6.22	N/A
Immatics	$54.60M	23.38	-$222.26M	-$1.99	N/A

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 4 more articles in the media than Immatics. MarketBeat recorded 5 mentions for CRISPR Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat CRISPR Therapeutics' score of 0.64 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
CRISPR Therapeutics	Positive
Immatics	Very Positive

Summary

CRISPR Therapeutics beats Immatics on 9 of the 17 factors compared between the two stocks.

How does Immatics compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Travere Therapeutics had 3 more articles in the media than Immatics. MarketBeat recorded 4 mentions for Travere Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat Travere Therapeutics' score of 1.03 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Travere Therapeutics	Positive
Immatics	Very Positive

Travere Therapeutics presently has a consensus target price of $52.08, suggesting a potential downside of 11.50%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 118.49%. Given Immatics' higher possible upside, analysts plainly believe Immatics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Travere Therapeutics has higher revenue and earnings than Immatics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	11.15	-$25.55M	-$0.23	N/A
Immatics	$54.60M	23.38	-$222.26M	-$1.99	N/A

Travere Therapeutics has a net margin of -4.00% compared to Immatics' net margin of -572.35%. Travere Therapeutics' return on equity of -26.16% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
Immatics	-572.35%	-47.36%	-39.35%

Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Immatics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

64.4% of Immatics shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Travere Therapeutics beats Immatics on 10 of the 16 factors compared between the two stocks.

Get Immatics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMTX vs. The Competition

Export

Metric	Immatics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.28B	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-4.78	21.75	25.89	24.17
Price / Sales	23.38	336.15	545.01	100.37
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	2.33	8.31	10.75	6.38
Net Income	-$222.26M	$23.92M	$3.58B	$337.00M
7 Day Performance	-2.66%	1.93%	1.90%	-0.23%
1 Month Performance	-17.29%	-0.41%	-0.26%	-1.40%
1 Year Performance	75.32%	65.22%	34.39%	27.76%

Immatics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMTX Immatics	2.745 of 5 stars	$9.52 flat	$20.80 +118.5%	+75.3%	$1.28B	$54.60M	N/A	260	Positive News
TWST Twist Bioscience	1.3971 of 5 stars	$85.63 +0.5%	$71.60 -16.4%	+177.9%	$5.33B	$409.48M	N/A	990	Insider Trade Gap Down
XENE Xenon Pharmaceuticals	3.7402 of 5 stars	$54.59 -0.4%	$77.20 +41.4%	+84.4%	$5.28B	N/A	N/A	210	Gap Down
AMRX Amneal Pharmaceuticals	2.2134 of 5 stars	$16.49 +2.4%	$15.80 -4.2%	+111.9%	$5.26B	$3.05B	43.40	8,500	Analyst Downgrade
CRSP CRISPR Therapeutics	2.5669 of 5 stars	$54.06 -0.6%	$67.78 +25.4%	+15.6%	$5.21B	$1M	N/A	460	Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMTX) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immatics (IMTX) Competitors

IMTX vs. TWST, XENE, AMRX, CRSP, and TVTX

How does Immatics compare to Twist Bioscience?

Summary

How does Immatics compare to Xenon Pharmaceuticals?

Summary

How does Immatics compare to Amneal Pharmaceuticals?

Summary

How does Immatics compare to CRISPR Therapeutics?

Summary

How does Immatics compare to Travere Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immatics (IMTX) Competitors

IMTX vs. TWST, XENE, AMRX, CRSP, and TVTX

How does Immatics compare to Twist Bioscience?

Do institutionals and insiders hold more shares of TWST or IMTX?

Do analysts prefer TWST or IMTX?

Which has better earnings and valuation, TWST or IMTX?

Is TWST or IMTX more profitable?

Which has more volatility and risk, TWST or IMTX?

Does the media refer more to TWST or IMTX?

Summary

How does Immatics compare to Xenon Pharmaceuticals?

Do analysts rate XENE or IMTX?

Is XENE or IMTX more profitable?

Do institutionals & insiders believe in XENE or IMTX?

Does the media refer more to XENE or IMTX?

Which has more volatility & risk, XENE or IMTX?

Which has preferable earnings and valuation, XENE or IMTX?

Summary

How does Immatics compare to Amneal Pharmaceuticals?

Is AMRX or IMTX more profitable?

Which has higher valuation & earnings, AMRX or IMTX?

Do insiders & institutionals believe in AMRX or IMTX?

Does the media prefer AMRX or IMTX?

Do analysts rate AMRX or IMTX?

Which has more volatility & risk, AMRX or IMTX?

Summary

How does Immatics compare to CRISPR Therapeutics?

Which has more volatility & risk, CRSP or IMTX?

Do analysts prefer CRSP or IMTX?

Is CRSP or IMTX more profitable?

Which has better earnings & valuation, CRSP or IMTX?

Do insiders & institutionals have more ownership in CRSP or IMTX?

Does the media refer more to CRSP or IMTX?

Summary

How does Immatics compare to Travere Therapeutics?

Does the media favor TVTX or IMTX?

Do analysts rate TVTX or IMTX?

Which has preferable valuation and earnings, TVTX or IMTX?

Is TVTX or IMTX more profitable?

Which has more risk and volatility, TVTX or IMTX?

Do insiders & institutionals believe in TVTX or IMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools